These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9008491)

  • 21. Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group.
    Tawil R; Forrester J; Griggs RC; Mendell J; Kissel J; McDermott M; King W; Weiffenbach B; Figlewicz D
    Ann Neurol; 1996 Jun; 39(6):744-8. PubMed ID: 8651646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early onset facioscapulohumeral muscular dystrophy.
    Brouwer OF; Padberg GW; Bakker E; Wijmenga C; Frants RR
    Muscle Nerve Suppl; 1995; 2():S67-72. PubMed ID: 7739629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses.
    Arahata K; Ishihara T; Fukunaga H; Orimo S; Lee JH; Goto K; Nonaka I
    Muscle Nerve Suppl; 1995; 2():S56-66. PubMed ID: 7739627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy.
    Katz NK; Hogan J; Delbango R; Cernik C; Tawil R; Statland JM
    Brain; 2021 Dec; 144(11):3451-3460. PubMed ID: 34542603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Facioscapulohumeral dystrophy: a distinct regional myopathy with a novel molecular pathogenesis. FSH Consortium.
    Tawil R; Figlewicz DA; Griggs RC; Weiffenbach B
    Ann Neurol; 1998 Mar; 43(3):279-82. PubMed ID: 9506542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Genetic analysis of facioscapulohumeral muscular dystrophy (FSHD)].
    Goto K; Song MD; Lee JH; Arahata K
    Rinsho Shinkeigaku; 1995 Dec; 35(12):1416-8. PubMed ID: 8752415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical variability of facioscapulohumeral muscular dystrophy in Russia.
    Kazakov VM; Rudenko DI
    Muscle Nerve Suppl; 1995; 2():S85-95. PubMed ID: 7739632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy.
    Kissel JT; McDermott MP; Mendell JR; King WM; Pandya S; Griggs RC; Tawil R;
    Neurology; 2001 Oct; 57(8):1434-40. PubMed ID: 11673585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recommendations for the management of facioscapulohumeral muscular dystrophy in 2011.
    Attarian S; Salort-Campana E; Nguyen K; Behin A; Andoni Urtizberea J
    Rev Neurol (Paris); 2012 Dec; 168(12):910-8. PubMed ID: 22551571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural History of Facioscapulohumeral Dystrophy in Children: A 2-Year Follow-up.
    Dijkstra JN; Goselink RJM; van Alfen N; de Groot IJM; Pelsma M; van der Stoep N; Theelen T; van Engelen BGM; Voermans NC; Erasmus CE
    Neurology; 2021 Nov; 97(21):e2103-e2113. PubMed ID: 34675094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy.
    Osborne RJ; Welle S; Venance SL; Thornton CA; Tawil R
    Neurology; 2007 Feb; 68(8):569-77. PubMed ID: 17151338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD).
    Lunt PW; Jardine PE; Koch MC; Maynard J; Osborn M; Williams M; Harper PS; Upadhyaya M
    Hum Mol Genet; 1995 May; 4(5):951-8. PubMed ID: 7633457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of motor learning in facioscapulohumeral muscular dystrophy patients.
    Bakhtiary AH; Phoenix J; Edwards RH; Frostick SP
    Eur J Appl Physiol; 2000 Dec; 83(6):551-8. PubMed ID: 11192064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epilepsy and mental retardation in a subset of early onset 4q35-facioscapulohumeral muscular dystrophy.
    Funakoshi M; Goto K; Arahata K
    Neurology; 1998 Jun; 50(6):1791-4. PubMed ID: 9633729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efforts toward understanding the molecular basis of facioscapulohumeral muscular dystrophy.
    Altherr MR; Bengtsson U; Markovich RP; Winokur ST
    Muscle Nerve Suppl; 1995; 2():S32-8. PubMed ID: 7739623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early-onset facioscapulohumeral muscular dystrophy: two case reports.
    Okinaga A; Matsuoka T; Umeda J; Yanagihara I; Inui K; Nagai T; Okada S
    Brain Dev; 1997 Dec; 19(8):563-7. PubMed ID: 9440803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extreme variability of expression in monozygotic twins with FSH muscular dystrophy.
    Tawil R; Storvick D; Feasby TE; Weiffenbach B; Griggs RC
    Neurology; 1993 Feb; 43(2):345-8. PubMed ID: 8094896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upper extremity kinematics and muscle activation patterns in subjects with facioscapulohumeral dystrophy.
    Bergsma A; Murgia A; Cup EH; Verstegen PP; Meijer K; de Groot IJ
    Arch Phys Med Rehabil; 2014 Sep; 95(9):1731-41. PubMed ID: 24780289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hearing loss in facioscapulohumeral dystrophy.
    Voit T; Lamprecht A; Lenard HG; Goebel HH
    Eur J Pediatr; 1986 Sep; 145(4):280-5. PubMed ID: 3769995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical and genetical features of Japanese early-onset facioscapulohumeral muscular dystrophy].
    Yamanaka G; Goto K; Hayashi YK; Miyajima T; Hoshika A; Arahata K
    No To Hattatsu; 2002 Jul; 34(4):318-24. PubMed ID: 12134683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.